l e Roux Researchers obtained data from 262 adults who began using liraglutide or semaglutide from January 2023 to March 2024 and had at least two follow-up visits after GLP-1 initiation (mean age, 46 years
Results depend on individual factors like underlying health conditions, other medications you might be taking, and whether youre making lifestyle changes with improved nutrition, physical activity, sleep, and stress management
I believe the market was uniquely slow to recognize the potential of GLP-1s for several reasons specific to this drug class
People should not take exenatide if they have severe kidney disease, significantly slowed digestion or diabetic ketoacidosis
Addressing obesity through weight management strategies, including pharmacologic ones like GLP-1 receptor agonists, is a key component of reducing all operative risks, improving surgical outcomes, and enhancing the long-term success of orthopedic interventions
Med Arch
